Seres sells VOWST business to Nestlé for up to $100M cash plus milestones; issues $15M stock

Seres Therapeutics, Inc.

Cash payment of $100M at closing (net of ~$17.9M owed to Nestlé affiliate and ~CHF2M to Bacthera); $50M due Jan 2025, $25M July 2025.
Prepaid $60M milestone for $150M annual net sales; future milestones of $125M at $400M and $150M at $750M in sales.
Seres and Nestlé share 50/50 net profit/loss on VOWST in 2025 profit-sharing period.
Nestlé to purchase 14,285,715 shares at $1.05/share ($15M); Seres to register resale within 90 days.
Post-closing Seres to focus on SER-155 and other biotherapeutic candidates; stockholder vote required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.